Exemestane and Pitavastatin Interaction

Avoid
Mechanism-based 75% confidence

Exemestane and Pitavastatin have a potentially harmful interaction with 75% confidence. Both Exemestane and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Exemestane

Steroidal Aromatase Inhibitor | Irreversible Estrogen Control

Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site.

Half-life: ~24 hours Typical dose: 12.5mg EOD or 25mg E3D (estrogen management) pct, anabolic
androgen receptoraromatase androgenicaromatase inhibitorestrogenichepatotoxic
View full profile

Pitavastatin

HMG-CoA Reductase Inhibitor | Low-Interaction Statin

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface.

Half-life: ~12 hours Typical dose: 1-4 mg/day cardiovascular
aromatase aromatase inhibitorhepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Liver
moderate
Pituitary
low

Shared Safety Flags

2x 2 compounds share the aromatase-inhibitor safety flag (Exemestane, Pitavastatin). Monitor accordingly.
2x 2 hepatotoxic compounds (Exemestane, Pitavastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Exemestane, Pitavastatin). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Exemestane, Pitavastatin). Monitor accordingly.

Frequently Asked Questions

Can I take Exemestane with Pitavastatin?

Combining Exemestane with Pitavastatin is not recommended. Both Exemestane and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Exemestane and Pitavastatin safe together?

This combination carries significant risk. Both Exemestane and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Exemestane and Pitavastatin?

Both Exemestane and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Exemestane and Pitavastatin?

Exemestane has a half-life of ~24 hours and Pitavastatin has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Exemestane vs Pitavastatin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.